BioAtla (BCAB) announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma, OPSCC” which details clinical data from its investigational antibody-drug conjugate, ozuriftamab vedotin, Oz-V, at the International Papillomavirus Society Conference, taking place October 23-26, 2025, in Bangkok, Thailand.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB: